CG still has an interest in screening the decline in renal function in subjects with normal SCr who are at risk, such as diabetics and stage 1 and 2 CKD patients, as well as healthy subjects enrolled in clinical trials and pharmacokinetic studies. Thus, it may be early to replace CG by MDRD in drug studies. CG still is the better formula in the elderly. Both formulas are not safe in some populations.
No takes yet. Share an insight, caveat, or question.
Rafik Hélou (2010) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: